Moreover, a prospective study conducted by Stevens and collaborators demonstrated that the use of anti-TNF therapy and vedolizumab might even lead to an improvement in sleep, depression, and anxiety in patients with moderate to severe IBD, highlighting this aspect within 6 weeks of therapy, which was maintained up to 1 year [19]. This evidence concerns the gene TNF and depressive disorder.